← Eichor
Study identifier: NCT07027202 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Early Preventive Left Ventricle Unloading After VA-ECMO for Refractory Cardiogenic Shock

Condition: Cardiogenic Shock Acute  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseNA
Planned participants298
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used worldwide to treat severe cardiogenic shock. The survival rate of these patients has increased in the last decade, reaching 45-50% for patients with acute myocardial infarction (AMI), the most frequent indication of the technique, 50-60% for patients with end-stage dilated cardiomyopathy bridged to heart transplantation or long-term left ventricle assist device (LVAD) surgery, 60-70% for fulminant myocarditis, while it remains lower for post-cardiotomy cardiogenic shock (25-35%) and after cardiac arrest (20-40%). However, peripherally inserted VA-ECMO increases left ventricular (LV) afterload, that may lead to poorer clinical outcomes by fostering left ventricular distension, blood stagnation, aortic valve closure, all of which increasing pulmonary congestion and the need for mechanical ventilation and compromising myocardial recovery whenever it is possible, or delaying a bridge to a heart transplantation or long-term left ventricle assist device (LVAD) surgery for patients with end-stage cardiac dysfunction. Several methods have been proposed to reduce afterload after VA-ECMO, including the use of an intra-aortic balloon pump (IABP), balloon atrial septostomy, transseptal left atrial cannula insertion, and use of the left-sided Impella device (Abiomed, Danvers, MA, USA). The clinical benefits of left ventricular unloading have been suggested by many retrospective case-control studies, incl…

This description comes directly from the study's public registry record.

Talk to the study team

Alain COMBES, MD  ·  0142163818  ·  alain.combes@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (12)

CHU Clermont-Ferrand - Site Gabriel MontpiedClermont-Ferrand, FranceNot Yet Recruiting
Henri MondorCréteil, FranceNot Yet Recruiting
Hôpital CardiologiqueLille, FranceNot Yet Recruiting
APHP - hôpital Pitié-SalpêtrièreParis, FranceRecruiting
APHP - hôpital Pitié-SalpêtrièreParis, FranceNot Yet Recruiting
APHP - hôpital Pitié-SalpêtrièreParis, FranceNot Yet Recruiting
Hôpital Européen Georges PompidouParis, FranceNot Yet Recruiting
Hôpital du PontchaillouRennes, FranceNot Yet Recruiting
Nouvel Hôpital CivilStrasbourg, FranceNot Yet Recruiting
Nouvel hôpital civilStrasbourg, FranceNot Yet Recruiting
Hôpital RangueilToulouse, FranceNot Yet Recruiting
CHRU Nancy - hôpitaux de braboisVandœuvre-lès-Nancy, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07027202